Compare Fortinet Inc (FTNT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs GeneDx Holdings Corp — how do they compare? Fortinet Inc trades at $190.56 (market cap $138.75B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Fortinet Inc is far larger — about 68.7× GeneDx Holdings Corp's market cap, and Fortinet Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and GeneDx Holdings Corp for 19 Days on average.
| FTNT | WGS | |
|---|---|---|
Market Cap | $138.75B | $2.02B |
Volume | 2,956,908 | 734,640 |
Sector | Technology | Health |
52-Week High | $191.27 | $167.51 |
52-Week Low | $75.23 | $34.51 |
Typical Hold Time | 72 Days | 19 Days |
Enterprise Value | $135.17B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $189.28, down 1.04% on the day but near its 52-week high, supported by a bullish technical trend and strong moving averages. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 estimate. Revenue growth remains solid, climbing to $6.80 billion in 2025, while profitability metrics like a 28.17% net income margin and 117.44% ROE highlight operational efficiency. Recent news highlights AI-driven cybersecurity demand and raised 2026 guidance as key growth catalysts.
The outlook for FTNT is positive, driven by accelerating platform demand and AI security expansion, though elevated valuation ratios (P/E of 66.88) pose a risk if growth moderates. Analyst consensus leans bullish with a 42% buy rating, but the stock trades above the $158.64 average price target, suggesting near-term caution. Key risks include competitive pressures and execution challenges in sustaining high growth rates amid economic uncertainty.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
